Table 1. Demography and cancer history of the treatment naïve, advanced, kidney cancer patient involved.

Subject ID*	Sex	Age (years)	Date of diagnosis	Histology	Fuhrman's nuclear grade	Stage1 at the time of sampling	MSKCC2 at the time of sampling
M-C	M*	69	30/11/09	PAP II	n.a.*	IV	INTERMEDIATE
F-A	F	60	08/04/10	CC	2	IV	GOOD
M-R	M	68	22/02/11	CC	3	IV	GOOD
C-M	F	65	30/10/97	CC	n.a.	IV	GOOD
DL-M	F	43	11/03/10	PAP II	4	IV	INTERMEDIATE
C-A	M	66	22/08/02	CC	3.4	IV	GOOD
P-E	M	29	07/10/08	CC	3	IV	GOOD
R-L	M	62	02/09/10	CC	3	IV	GOOD
C-L	M	45	30/03/06	CC	3	IV	INTERMEDIATE
F-M	M	63	22/07/10	CC	4	IV	INTERMEDIATE
F-F	M	50	18/11/09	CC	3	IV	GOOD
Z-N	M	59	17/02/10	CC	2	IV	GOOD
U-E	F	80	03/12/07	CC	1.1	IV	INTERMEDIATE
C-Lu	M	37	29/11/09	CC	3	IV	GOOD
DM-T	M	69	10/04/08	PAP II	3	IV	INTERMEDIATE
M-CE	M	55	21/01/10	CC	2	IV	GOOD
G-F	M	45	23/12/10	HLRCC *	3.4	IV	GOOD
M-G	M	64	07/01/09	CC	2	IV	GOOD

¹Stage is indicated accrding to the 2002 TNM staging system;.

²MSKCC Motzer prognostic score for advanced kidney cancer patients; it includes 5 parameters:

- Karnofsky performance status <80%;

- Haemoglobin levels < normal lower limits;

- LDH serum levels >1.5 time the normal upper limit level;

- Corrected calcium >10 mg/dL;

- Absence of prior nephroctomy.

If a patient meets more than 2 criteria the prognosis is POOR, if meets 1–2 criteria is INTERMEDIATE, if meets no criteria is GOOD.

^*Abbreviations: ID for “identity”; M for male patients; F for female patients; PAP II for the “Papillary type II” histology; CC for “Clear Cell” histology; HLRCC for “Hereditary leyomiomatosis renal cell carcinoma”; n.a. for “not applicable”.